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2809syndrome (4). Regarding the coronary plaque pro-
gression/regression, we showed in the PRECISE-IVUS
that the atherogenic small dense LDL-C level was
signiﬁcantly suppressed in patients with plaque
regression compared with patients with plaque pro-
gression. In addition, the combination of a statin and
ezetimibe showed a greater reduction in small
dense LDL-C levels in diabetic patients compared
with higher dose statin monotherapy (5). Similar to
the consideration by Dr. Koh, these ﬁndings thus
may explain the clinical beneﬁt of a dual lipid-
lowering strategy observed in the PRECISE-IVUS and
IMPROVE-IT (Examining Outcomes in Subjects with
Acute Coronary Syndrome: Vytorin (Ezetimibe/Sim-
vastatin) studies, indicating the expected efﬁcacy in
high-risk patients such as those with diabetes, and
warrant further studies to conﬁrm these mechanis-
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Control in Type 1 Diabetes
With Long-Term Risk
After CABGWith great interest, we read the recent article by
Nyström et al. (1) assessing the relationships of
preoperative glycemic control in type 1 diabetes and
long-term risks of major adverse cardiovascular
events (MACE) and all-cause mortality after coronary
artery bypass grafting (CABG) in an observational
cohort study. They showed that preoperative poor
glycemic control deﬁned by hemoglobin A1c levels
was associated with increased long-term risks of
MACE and all-cause mortality. The strengths of this
study include the large sample of patients with a
long follow-up and use of appropriate statistical
methods to estimate the relationships of preopera-
tive glycemic control with the risks of MACE and all-
cause mortality. In our view, however, several issues
in this study seemed not to be well addressed.
First, perioperative blood management was not
included in the study design. It has been shown that
preoperative anemia is common among patients un-
dergoing CABG and is an important risk factor for
early and late mortality after surgery (2). Further-
more, the combined mortality risk of pre-operative
anemia and perioperative transfusion is nearly triple
that of nonanemic patients not receiving transfusion.
In addition, post-operative anemia is also common,
with an incidence of 44% and frequently persists for
months after CABG. When the postoperative hemo-
globin level is considered a continuous variable,
every 1-mg/dl decrease in hemoglobin level is asso-
ciated with a 13% increase in MACE and a 22% in-
crease in all-cause mortality (3). We are concerned
that the existence of any imbalance in these factors
among patients with the different hemoglobin A1c
levels would have confounded interpretation of their
results.
Second, the variables used for adjusted hazard
ratios of MACE and long-term all-cause mortality in
the multivariable model only included the baseline
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not important post-operative risk factors. If surgery
is successful, CABG should improve postoperative
cardiac function, physical health status, and quality
of life in most of patients. It has been shown
that established preoperative risk factors are not
good predictors of adverse outcomes and long-term
survival after CABG (4). Actually, late mortality is
mainly attributable to many causes, not necessarily
related to patients’ cardiovascular and general
health before CABG. The available literature pro-
vides compelling evidence that postoperative com-
plications and persistent vital organ dysfunctions at
hospital discharge are important predictors of late
mortality after cardiac surgery (5). For example,
deep sternal wound infection or mediastinitis, acute
myocardial and kidney injuries, pulmonary com-
plications, dysfunction or loss of bypass grafts, new-
onset atrial ﬁbrillation, and deterioration of regional
wall motion after CABG have been associated inde-
pendently with increased MACE and long-term
mortality. Furthermore, hemoglobin A1c is a marker
of glycemic control over the previous 3 months before
measurement. Can preoperative hemoglobin A1c levels
exactly represent the postoperative long-term glyce-
mic control of patients? Thus, we argue that no inclu-
sion of important postoperative risk factors in the
multivariable model for adjusted hazard ratios would
have biased the true effect of preoperative glycemic
control on long-term outcomes after CABG in this
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Crit Care Med 2014;42:2069–74.REPLY: Association of Glycemic Control
in Type 1 Diabetes With Long-Term Risk
After CABGWe thank Dr. Xue and colleagues for their interest
and comments regarding our paper (1). Dr. Xue and
colleagues were concerned that the lack of informa-
tion regarding pre- and post-operative hemoglobin
levels and perioperative transfusions in our study
would have biased the results. We did not have this
information, and we agree that information regarding
pre-operative hemoglobin levels would have been
interesting because hemoglobin level has been shown
to be associated with HbA1c in patients with type 2
diabetes (2). However, because the association be-
tween hemoglobin level and HbA1c in previous
studies was very weak (2), we ﬁnd it unlikely that the
lack of information regarding preoperative hemoglo-
bin levels inﬂuenced our main ﬁndings that poor
glycemic control was associated with increased long-
term risk of death or a major adverse cardiovascular
event.
Dr. Xue and colleagues also expressed concern
regarding the variables included in the multivariable
models used to estimate adjusted hazard ratios for
the association between HbA1c categories and a
combination of death or a major adverse cardiovas-
cular event. They argued that we should have
included post-operative complications in the multi-
variable models. We disagree because control for in-
termediates (i.e., factors that are on the causal
pathway between the exposure and the outcome,
such as post-operative complications) will generally
bias estimates of the effect toward no effect (3).
Last, Dr. Xue and colleagues stated that it has been
shown that “established preoperative risk factors
are not good predictors of adverse outcomes and
long-term survival after CABG.” We wish to empha-
size that well-known cardiac surgery risk predic-
tion models, although developed for assessment of
